Publication

Article

Pharmaceutical Technology

Pharmaceutical Technology-12-02-2003
Volume27
Issue 12

A State of Revision: USP's Guideline for the Submission of Requests for Revision

Author(s):

Eric B. Sheinin, PhD

USP's new guideline will assist the industry to help set the monograph standards by which the industry must abide. This column suggests how to apply the guideline to gain maximum benefit.

External Link - article-78319.pdf

Articles in this issue
December 2003
All Signs Indicate a Strong 2004 for Contract Services
Behavior of Uptake of Moisture by Drugs and Excipients
A State of Revision: USP's Guideline for the Submission of Requests for Revision
Targeted Cationic Liposomes, Technologies, and Developments
Sixth Annual International Employment Survey: Staying the Course
Drug Pricing Concerns Shape Policy Decisions in 2003
In the Spotlight--January 2004
December 2003

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
Sand running through the bulbs of an hourglass | Image Credit: © BillionPhotos.com - stock.adobe.com
July 24th 2025

Customizable Relationships Enhance Speed to Market

Patrick Lavery
While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com
July 23rd 2025

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

Siegfried Schmitt
Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.
Site Logo
March 28th 2025

Transformations in Drug Development for Cell and Gene Therapies

PPD Thermo Fisher Scientific
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
3d render. Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. COVID-19 mRNA vaccine production platform. | Image Credit: © wacomka - stock.adobe.com
July 22nd 2025

Pack Expo Las Vegas Marks 30th Anniversary with New Experiences for 2025

Patrick Lavery
The trade show is expected to draw 35,000 attendees to a show floor netting more than 1 million square feet.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney
The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.